Editor's Review,TRULICITY is used to improve blood sugar control

The landscape of weight management is continually evolving, with a growing interest in pharmacological interventions. For individuals in Australia seeking effective weight reduction strategies, particularly those without diabetes, the role of medications like dulaglutide is a subject of significant discussion. While dulaglutide, marketed under the brand name Trulicity, is primarily approved for the treatment of type 2 diabetes, emerging research and clinical observations suggest potential benefits for weight loss in non-diabetic individuals. However, it's crucial to approach this with a clear understanding of its indications and limitations.

Dulaglutide's Mechanism of Action and Weight Management Potential

Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. This class of medications works by mimicking the action of the natural incretin hormone GLP-1. In individuals with type 2 diabetes, dulaglutide aids in improving glycaemic control through several mechanisms. It stimulates the pancreas to release more insulin after meals, slows down the emptying of the stomach, and reduces the liver's production of glucose. These actions collectively help to lower blood glucose levels.

Beyond its glycaemic benefits, a notable secondary effect observed in clinical trials and real-world settings is weight loss. Studies have indicated that dulaglutide can lead to clinically significant weight reduction. For instance, some research suggests that dulaglutide was as effective as, if not superior to, other treatments in achieving weight loss. One case report even documented a substantial weight loss of 40 kg (a reduction of 21%) and a BMI decrease of 10.3 kg/m² over a six-month period with dulaglutide use, with no reported side effects. Another study observed a significant weight reduction of 3.3 kg after 24 months of dulaglutide therapy. In a real-world practice setting, once-weekly dulaglutide demonstrated greater weight loss compared to insulin, with the dulaglutide group losing an average of 2.4 kg compared to a gain of 2.0 kg in the insulin group at six months.

The mechanism by which dulaglutide promotes weight loss is thought to be partly through increased satiety, leading to reduced food intake. It may also improve adherence to a low-energy diet. While some individuals have lost up to 10 pounds with Trulicity, it's important to note that Trulicity is not a weight loss drug and is not indicated for this specific purpose.

Dulaglutide for Weight Loss in Non-Diabetic Individuals: Current Landscape in Australia

In Australia, the regulatory landscape for weight management medications is specific. Currently, only liraglutide (Saxenda) is TGA approved for the indication of weight loss. Semaglutide (Ozempic) is approved for weight loss in other regions like the US. This means that while dulaglutide can lead to weight loss as a secondary benefit, its use solely for weight loss in non-diabetic individuals is not officially approved.

The Australian Prescriber highlights the efficacy and safety of semaglutide for weight loss in obesity without diabetes. While semaglutide appears to be more effective for weight loss than dulaglutide and liraglutide, dulaglutide is still a GLP-1 RA marketed in Australia. Public Summary Documents from PBAC meetings indicate discussions around higher doses of dulaglutide (3mg and 4.5mg), which are associated with greater reductions in HbA1c and more weight loss, being available internationally.

For individuals seeking weight loss without diabetes, other medications specifically licensed for obesity management may be more appropriate. Giving Trulicity only for weight loss, especially in a non-diabetic, should not be done according to some expert opinions. The general consensus is that Trulicity should be used along with diet and exercise.

Considerations and Alternatives

When considering dulaglutide for weight loss in Australia without diabetes, several factors are paramount:

* Off-Label Use: Prescribing dulaglutide for weight management in non-diabetic individuals would constitute off-label use. This requires careful consideration by a healthcare professional, weighing the potential benefits against the risks.

* Not a Standalone Solution: Like most weight management strategies, dulaglutide is most effective when combined with a healthy diet and regular exercise. Trulicity is indicated as an adjunct to diet and exercise for its approved indications.

* Potential Side Effects: While some users experience no side effects, potential adverse effects of GLP-1 receptor agonists can include nausea, vomiting, diarrhea, and abdominal pain. Although dulaglutide is generally associated with a reduced risk of hypoglycemia, it can still